VelaLabs’s Support for International Clients
Within the Tentamus Group, VelaLabs is specialized for characterization of biosimilars and supports its customers with complete analytics and tools for nearly all biomolecules. All dedicated methods are either routinely established or will be developed upon client request. A typical panel of methods is shown e.g. for trastuzumab (originator product already on the market: Herceptin®) indicated for the treatment of certain metastatic breast or gastric cancers (see table).
Moreover, VelaLabs has considerable background knowledge with respect to mode-of action, comparability studies, patent & market situation, post approval activities, and the highly competitive field for these biomolecules. For more than 20 blockbuster drugs, VelaLabs has compiled fact sheets, which are free for download (from their website) for our clients and other interested parties.
See our abstract:
Biosimilars – A growing business segment in the near future
(Zimmermann, Fido et al)
For any more information, consultations or questions please contact Flora Rostemi (f.rostemi@vela-labs.at)
Tentamus Group GmbH was founded in 2011. Tentamus is a global product and safety group with a core presence in Europe, UK, Israel, China and the USA. Accredited and licensed Tentamus Group tests, audits and consults on all products involving the human body (food & feed, pharmaceuticals & medical, agrochemicals, cosmetics, agriculture & environment and nutraceutical & supplements). Tentamus Group is represented in over 40 locations worldwide. More than 1,600 highly-trained staff members work in over 1 million square feet of laboratory and office spaces. For further information please visit www.tentamus.com.
Tentamus Group
An der Industriebahn 5
13088 Berlin, Germany
www.tentamus.com
Tentamus Group GmbH
An der Industriebahn 26
13088 Berlin
Telefon: +49 (30) 206038-230
Telefax: +49 (30) 206038-190
http://www.tentamus.com
VelaLabs – Assistant to Senior Management
E-Mail: f.rostemi@vela-labs.at
